Form 8-K - Current report:
SEC Accession No. 0001641172-25-002750
Filing Date
2025-04-04
Accepted
2025-04-04 16:05:34
Documents
14
Period of Report
2025-03-31
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38689
2 ex4-1.htm EX-4.1 118017
  Complete submission text file 0001641172-25-002750.txt   356530

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gtbp-20250331.xsd EX-101.SCH 3024
4 XBRL LABEL FILE gtbp-20250331_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE gtbp-20250331_pre.xml EX-101.PRE 24171
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3680
Mailing Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111
Business Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

EIN.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 25813982
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)